Clinical Trial Update: Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating lenalidomide plus ofatumumab for relapsed or refractory non-Hodgkin's lymphoma was completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: University of Nebraska | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-08-08